Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 6, 2007 - Issue 6
Submit an article Journal homepage
137
Views
17
CrossRef citations to date
0
Altmetric
Review

The safety of amodiaquine use in pregnant women

Harry K Tagbor Kwame Nkrumah University of Science and Technology, Department of Community Health, School of Medical Sciences, Private Mail Bag, University Post Office, Kumasi, Ghana [email protected]
,
Daniel Chandramohan London School of Hygiene and Tropical Medicine, London, UK
&
Brian Greenwood London School of Hygiene and Tropical Medicine, London, UK
Pages 631-635 | Published online: 30 Oct 2007

Bibliography

  • MENENDEZ C: Malaria during pregnancy: a priority area of malaria research and control. Parasitol. Today (1995) 11:178-183.
  • WHO: The World Health Report – 1998. World Health Organisation (1998).
  • WHO: A Strategic Framework for Malaria Prevention and Control during Pregnancy in the African Region. WHO Regional Office for Africa (2004).
  • SCHAPIRA A: The resistance of falciparum-malaria in Africa to 4-aminoquinolines and antifolates. Scand. J. Infect. Dis. (1990):6-64.
  • NEWMAN RD, PARISE ME, SLUTSKER L, NAHLEN B, STEKETEE RW: Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop. Med. Int. Health (2003) 8(6):488-506.
  • THOMAS F, ERHART A, D'ALESSANDRO U: Can amodiaquine be used safely during pregnancy? Lancet Infect. Dis. (2004) 4(4):235-239.
  • WHO: The Use of Antimalarial Drugs. Report of a WHO Informal Consultation. WHO/CDS/RBM/2001.33 (2000).
  • WINSTANLEY P, WARD S, SNOW R, BRECKENRIDGE A: Therapy of falciparum malaria in sub-Saharan Africa: from molecule to policy. Clin. Microbiol. Rev. (2004) 17:612-637.
  • VERDIER F, PUSSARD E, BLAYO MC: Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines. Med. Trop. (Mars) (1986) 46(4):329-343.
  • WINSTANLEY PA, SIMOOYA O, KOFI EKUE JM et al.: The disposition of amodiaquine in Zambians and Nigerians with malaria. Br. J. Clin. Pharmacol. (1990) 29(6):695-701.
  • WINSTANLEY P: The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. Br. J. Clin. Pharmacol. (1990) 29:479-485.
  • BRASSEUR P, GUIGUEMDE R, DIALLO S et al.: Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:645-650.
  • OLLIARO P, NEVILL C, LEBRAS J et al.: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 348:1196-1201.
  • OLLIARO P, MUSSANO P: Amodiaquine for treating malaria. Cochrane Database Syst. Rev. (2003) 2:CD000016.
  • OLLIARO PL, TAYLOR WRJ: Antimalarial compounds: from bench to bedside. J. Exp. Bio. (2003) 206(21):3753-3759.
  • ABACASSAMO F, ENOSSE S, APONTE JJ et al.: Efficacy of chloroquine, amodiaquine, sulphadoxine–pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop. Med. Int. Health (2004) 9:200-208.
  • DORSEY G, NJAMA D, KAMYA MR et al.: Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 360:2031-2038.
  • MOCKENHAUPT FP, EHRHARDT S, DZISI SY et al.: A randomized, placebo-controlled, double-blind trial on sulfadoxine–pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop. Med. Int. Health (2005) 10:512-520.
  • ODURO AR, ANYORIGIYA T, HODGSON A et al.: A randomized comparative study of chloroquine, amodiaquine and sulphadoxine–pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop. Med. Int. Health (2005) 10:279-284.
  • STAEDKE SG, KAMYA MR, DORSEY G et al.: Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet (2001) 358:368-374.
  • MEREMIKWU M, ALARIBE A, EJEMOT R et al.: Artemether–lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar. J. (2006) 5(1):43.
  • VAN DEN BROEK I, AMSALU R, BALASEGARAM M et al.: Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malar. J. (2005) 4(1):14.
  • BONNET M, ROPER C, FÉLIX M et al.: Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine–pyrimethamine in N'ZÉrÉkorÉ. Malar. J. (2007) 6(1):54.
  • MÉNARD D, ANDRIANINA N, RAMIANDRASOA Z et al.: Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar. Malar. J. (2007) 6(1):65.
  • FAYE B, NDIAYE J-L, NDIAYE D et al.: Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. (2007) 6(1):80.
  • BLAIR S, CARMONA-FONSECA J, PIÑEROS J et al.: Therapeutic efficacy test in malaria falciparum in Antioquia, Colombia. Malar. J. (2006) 5(1):14.
  • THET N, HLA W, YIN YIN N: Falciparum malaria and pregnancy: relationship and treatment response. Southeast Asian J. Trop. Med. Public Health (1988) 19(2):253-258.
  • TAGBOR H, BRUCE J, BROWNE E et al.: Efficacy, safety and tolerability of amodiaquine and sulphadoxine–pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet (2006) 368:1349-1356.
  • STEKETEE RW, BRANDLING-BENNETT AD, KASEJE DCO, SCHWARTZ IK, CHURCHILL FC: In vivo response of Plasmodium falciparum to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya. Bull. World Health Organ. (1987) 65:885-890.
  • STEKETEE R, MACHESO A, HEYMANN D et al.: A decade of progress in malaria policy and program development in Malawi: 1984 – 1993. (1995):USAID Document no. AOT-0483-P-HI-2171, Washington, DC, USA.
  • MEIN RM: Camoquin in the treatment of human malaria. Am. J. Trop. Med. Hyg. (1951) 31(2):212-217.
  • MCDERMOTT JM, HEYMANN DL, WIRIMA JJ et al.: Efficacy of chemoprophylaxis in preventing Plasmodium falciparum parasitaemia and placental infection in pregnant women in Malawi. Trans. R. Soc. Trop. Med. Hyg. (1988) 82:520-523.
  • NEFTEL KA, WOODTLY W, SCHMID M, FRICK PG, FEHR J: Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. (1986) 297:721.
  • HATTON CSR, PETO TEA, BUNCH C et al.: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 1:411-414.
  • PHILLIPS-HOWARD PA, WEST LJ: Serious adverse drug reactions to pyrimethamine–sulphadoxine, pyrimethamine–dapsone and to amodiaquine in Britain. J. Royal Soc. Med. (1990) 83:82-85.
  • RHODES EGH, BALL J, FRANKLIN M: Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. BMJ (1986) 292:717.
  • STURCHLER D, SCHAR M, GYR N: Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis. J. Trop. Med. Hyg. (1987) 90:239-243.
  • BRASSEUR P, AGNAMEY P, EKOBO AS et al.: Sensitivity of Plasmodium falciparum to amodiaquine and chloroquine in central Africa: a comparative study in vivo and in vitro. Trans. R. Soc. Trop. Med. Hyg. (1995) 89:528-530.
  • SOWUNMI A, AYEDE AI, FALADE AG et al.: Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Ann. Trop. Med. Parasitol. (2001) 95:549-558.
  • NGOUESSE B, BASCO LK, RINGWALD P, KEUNDJIAN A, BLACKETT KN: Cardiac effects of amodiaquine and sulfadoxine–pyrimethamine in malaria-infected African patients. Am. J. Trop. Med. Hyg. (2001) 65:711-716.
  • AKPALU AK Jr, NYAME PK, DODOO ANO: Amodiaquine-induced dystonic reactions: case reports and implications for policy change in Ghana. Int. J. Risk Saf. Med. (2005) 17(1-2):1.
  • BASCO LK, NGANE VF, NDOUNGA M et al.: Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine–pyrimethamine monotherapies in children before national drug policy change. Am. J. Trop. Med. Hyg. (2006) 75(3):388-395.
  • EANMAT: The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop. Med. Int. Health (2003) 8:860-867.
  • NDUMBE PM: Curative and preventive treatment of uncomplicated malaria in public health institutions in Cameroon. Eur. J. Epidemiol. (1989) 5(2):183-188.
  • WHO: Antimalarial Drug Combination Therapy, Report of a WHO Technical Consultation. WHO/CDS/RBM/2001.35. (2001).
  • TALISUNA A, STAEDKE S, D'ALESSANDRO U: Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar. J. (2006) 5(1):50.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.